{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-000725","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.054957+00:00","generated_at":"2026-06-20T17:57:39.269283+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"C4 Therapeutics announces 2023 priorities, Phase 1 data expected in 2H 2023 for CFT7455 and CFT8634","bullets":["Cash, cash equivalents and marketable securities of $366M as of Sep 30, 2022; expected to fund operations to end of 2024.","Phase 1/2 trial of CFT7455 (IKZF1/3 degrader for multiple myeloma) continues; Phase 1 dose escalation data expected in 2H 2023.","Phase 1/2 trial of CFT8634 (BRD9 degrader for synovial sarcoma) continues; Phase 1 data expected in 2H 2023; PK/PD data supportive of proof of mechanism.","Phase 1/2 trial of CFT1946 (BRAF-V600 degrader for solid tumors) initiated; IND submission for CFT8919 (EGFR L858R NSCLC) planned in 1H 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-000725","json":"https://secwatch.observer/filing/0001628280-23-000725.json","markdown":"https://secwatch.observer/filing/0001628280-23-000725.md","text":"https://secwatch.observer/filing/0001628280-23-000725.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828023000725/0001628280-23-000725-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828023000725/cccc-20230109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:57:39.269283+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}